Masaki Y, Kawabata H, Takai K, Tsukamoto N, Fujimoto S, Ishigaki Y, et al. 2019 Updated diagnostic criteria and disease severity classification for TAFRO syndrome. Int J Hematol. 2020;111:155–8.

Article  PubMed  Google Scholar 

Takai K, Nikkuni K, Shibuya H, Hashidate H. Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Rinsho Ketsueki. 2010;51:320–5.

PubMed  Google Scholar 

Masaki Y, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome. Ann Hematol. 2022;101:485–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nishimura Y, Faigenbaum DC, Pierson SK, et al. Validated international definition of the TAFRO clinical subtype of idiopathic multicentric Castleman disease. Am J Hematol. 2021;96(10):1241–52.

Article  PubMed  PubMed Central  Google Scholar 

Fujimoto S, Sakai T, Kawabata H, Kurose N, Yamada S, Takai K, et al. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Am J Hematol. 2019;94:975–83.

Article  CAS  PubMed  Google Scholar 

Kawabata H, Fujimoto S, Sakai T, et al. Patient’s age and D-dimer levels predict the prognosis in patients with TAFRO syndrome. Int J Hematol. 2021;114:179–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.

Article  PubMed  PubMed Central  Google Scholar 

Allegra A, Rotondo F, Russo S, et al. Castleman-Kojima disease (TAFRO syndrome) in a Caucasian patient: a rare case report and review of the literature. Blood Cells Mol Dis. 2015;55(3):206–7.

Article  PubMed  Google Scholar 

Iwasaki T, Kuragano T, et al. TAFRO syndrome with renal biopsy successfully treated with steroids and cyclosporine: a case report. BMC Nephrol. 2022;23:262.

Article  PubMed  PubMed Central  Google Scholar 

Watanabe M, Haji Y, Hozumi M, et al. Combined B-cell immunomodulation with rituximab and belimumab in severe, refractory TAFRO syndrome associated with Sjögren’s syndrome: A case report. Mod Rheumatol Case Rep. 2023;7(2):475–9.

Article  PubMed  Google Scholar 

Yin X, Liu Y, Zhong C, et al. Rituximab-bortezomib-dexamethasone induce high response rates in iMCD in clinical practice. Br J Haematol. 2023;203(5):803–6.

Article  CAS  PubMed  Google Scholar 

Kakutani T, Nunokawa T, Chinen N, et al. Treatment-resistant idiopathic multicentric Castleman disease with thrombocytopenia, anasarca, fever, reticulin fibrosis, renal dysfunction, and organomegaly managed with Janus kinase inhibitors: a case report. Medicine. 2022;101(48): e32200.

Article  PubMed  PubMed Central  Google Scholar 

Pierson SK, Lim MS, Srkalovic G, Brandstadter JD, Sarmiento Bustamante M, Shyamsundar S, et al. Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes. Blood Adv. 2023;7(21):6652–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115–24.

Article  PubMed  PubMed Central  Google Scholar 

Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020;135(16):1353–64.

Article  PubMed  Google Scholar 

Sakaki A, Hosoi H, Kosako H, et al. Successful combination treatment with rituximab, steroid pulse therapy, plasma exchange and romiplostim for very severe TAFRO syndrome. Leuk Lymphoma. 2022;63(10):2499–502.

Article  CAS  PubMed  Google Scholar 

Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric castleman disease. Am J Hematol. 2016;91:220–6.

Article  CAS  PubMed  Google Scholar 

José FF, Kerbauy LN, Perini GF, Blumenschein DI, Pasqualin DDC, Malheiros DMAC, et al. A life-threatening case of TAFRO syndrome with dramatic response to tocilizumab, rituximab, and pulse steroids: the first case report in Latin America. Medicine. 2017;96: e6271.

Article  PubMed  PubMed Central  Google Scholar 

Ozeki T, Tsuji M, Yamamoto J, Shigematsu C, Maruyama S. Thrombotic microangiopathy on kidney biopsy in a patient with TAFRO syndrome. CEN Case Rep. 2018;7:243–7.

Article  PubMed  PubMed Central  Google Scholar 

Mizuno H, Sekine A, Oguro M, Oshima Y, Kawada M, Sumida K, et al. Renal histology in a patient with TAFRO syndrome: a case report. Hum Pathol. 2018;82:258–63.

Article  PubMed  Google Scholar 

Noda-Narita S, Sumida K, Sekine A, Hoshino J, Mise K, Suwabe T, et al. TAFRO syndrome with refractory thrombocytopenia responding to tocilizumab and romiplostim: a case report. CEN Case Rep. 2018;7:162–8.

Article  PubMed  PubMed Central  Google Scholar 

Nakamori A, Akagaki F, Yamaguchi Y, Arima R, Sugiura T. Nephrotic syndrome with thrombocytopenia, lymphadenopathy, systemic inflammation, and splenomegaly. Intern Med. 2018;57:1123–9.

Article  PubMed  Google Scholar 

Tanaka M, Tsujimoto H, Yamamoto K, Shimoda S, Oka K, Takeoka H. Clinicopathological features of progressive renal involvement in TAFRO syndrome: a case report and literature review. Medicine. 2017;96: e8216.

Article  PubMed  PubMed Central  Google Scholar 

Mizuno H, Sawa N, Watanabe S, et al. The clinical and histopathological feature of renal manifestation of TAFRO syndrome. Kidney Int Rep. 2020;5:1172–9.

Article  PubMed  PubMed Central  Google Scholar 

Furuto Y, Hashimoto H, et al. Membranoproliferative glomerulonephritis-like finding for TAFRO syndrome, associated with an anterior mediastinal tumor. Medicine. 2018;97(24):e11057.

Leurs A, Gnemmi V, Terriou L, et al. Renal pathologic findings in TAFRO syndrome: is there a continuum between thrombotic microangiopathy and membranoproliferative glomerulonephritis? A case report and literature review. Front Immunol. 2019:10:1489.

Saito H, Tanaka K, Kazama J, et al. Pathological finding of progressive renal involvement in a patient with TAFRO syndrome. CEN case report. 2019;8:239–45.

Article  Google Scholar 

Nagayama Y, Yamato M, Matsui K, et al. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. BMC Nephrol. 2019;20:375.

Article  PubMed  PubMed Central  Google Scholar 

Simeni Njonnou SR, Deuson J, et al. Unexplained cause of thrombocytopenia, fever, anasarca and hypothyroidism: TAFRO syndrome with thrombotic microangiopathy renal histology. BMJ Case Report. 2020;13:e234155.

Article  Google Scholar 

Zhou Q, Xhang Y, et al. Kidney biopsy findings in two patients with TAFRO syndrome: case presentations and review of the literature. BMC Nephrol. 2020;21(1):499.

Article  PubMed  PubMed Central  Google Scholar 

Shimada K, Sasaki T, Okabe M, et al. TAFRO syndrome with kidney involvement: a case series of patients with kidney biopsies. Kidney Med. 2021;2:286–93.

Article  Google Scholar 

Nakayama Y, Mizuno H, Ubara Y, et al. Adolescent-onset TAFRO syndrome with malignant nephrosclerosis-like lesions. Intern Med. 2023;62:2223–9.

Article  PubMed  Google Scholar 

Sato H, Kanno A, Fukukawa K, et al. Case report: acase of TAFRO syndrome with severe and prolonged thrombocytopenia: diagnostic pitfalls. Front Immunol. 2023;14:1266187.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Naomi S, Takashi Y, Kensuke T, Hiruta H, Tomoaki MA, Ichiro T. A case of tafro syndrome who showed remarkable elevation of presepsin level without an apparent infectious disease. J Jpn Soc Lab Med. 2022;70:29–34.